



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G06F	A2	(11) International Publication Number: WO 99/52025 (43) International Publication Date: 14 October 1999 (14.10.99)
(21) International Application Number: PCT/US99/07171 (22) International Filing Date: 1 April 1999 (01.04.99) (30) Priority Data: 60/080,629 3 April 1998 (03.04.98) US (71) Applicant (for all designated States except US): TRIANGLE PHARMACEUTICALS, INC. [US/US]; 4 University Place, 4611 University Drive, Durham, NC 27707 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BARRY, David, W. [US/US]; 1810 South Lakeshore Drive, Chapel Hill, NC 27514 (US). UNDERWOOD, Carolyn, S. [US/US]; 108 Parchment Court, Cary, NC 27511 (US). McCREEDY, Bruce, J. [US/US]; 100 Berryhill Drive, Raleigh, NC 27615 (US). HADDEN, David, D. [US/US]; 2307 Whitley Drive, Durham, NC 27707 (US). LUCAS, Jason, L. [US/US]; 1215 Gateway Lane, West Chester, PA 19355 (US). (74) Agents: BODDIE, Needham, J., II et al.; Myers, Bigel, Sibley, & Sajovec, P.A., P.O. Box 37428, Raleigh, NC 27627 (US).		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: SYSTEMS, METHODS AND COMPUTER PROGRAM PRODUCTS FOR GUIDING THE SELECTION OF THERAPEUTIC TREATMENT REGIMENS		
(57) Abstract <p>Systems, methods and computer program products for guiding selection of a therapeutic treatment regimen for a known disease such as HIV infection are disclosed. The method comprises (a) providing patient information to a computing device; the computer device comprising: a first knowledge base comprising a plurality of different therapeutic treatment regimens for the disease; a second knowledge base comprising a plurality of expert rules for selecting a therapeutic treatment regimen for the disease; and a third knowledge base comprising advisory information useful for the treatment of a patient with different constituents of the different therapeutic treatment regimens; and (b) generating in the computing device a listing (preferably a ranked listing) of therapeutic treatment regimens for the patient; and (c) generating in the computing device advisory information for one or more treatment regimens in the listing based on the patient information and the expert rules.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SYSTEMS, METHODS AND COMPUTER PROGRAM PRODUCTS FOR GUIDING THE SELECTION OF THERAPEUTIC TREATMENT REGIMENS

A portion of the disclosure of this patent document contains material that is the subject of copyright protection. The copyright owner does not object to the reproduction of the patent disclosure as it appears in the public patent files of the United States Patent and Trademark Office, but otherwise reserves all other rights in the copyrighted material.

Related Applications

This application claims the benefit of U.S. Provisional Application No. 60/080,629 filed April 3, 1998.

Field of the Invention

This invention concerns systems, methods and computer program products for guiding the selection of therapeutic treatment regimens for complex disorders such as cancer and HIV-1 infection, wherein a ranking of available treatment regimens is generated and advisory information clinically useful for treating patients is provided.

Background of the Invention

Therapeutic treatment regimens for disorders such as HIV-1 infection (acquired immune deficiency syndrome or AIDS) and cancer are increasingly complex.

5 New data and new therapeutic treatment regimens continue to modify the treatments available, and it is difficult for all but the specialist to remain current on the latest treatment information. Further, even those who are current on the latest treatment

10 information require time to assimilate that information and understand how it relates to other treatment information in order to provide the best available treatment for a patient. Combination therapeutic treatment regimens exacerbate this problem by making

15 potential drug interactions even more complex. Finally, an increasingly sophisticated patient population, in the face of a vast volume of consumer information on the treatment of disease, makes the mere statement of a treatment regime, without explanation, difficult for

20 the patient to accept.

R. Miller et al., *Summary Recommendations for Responsible Monitoring and Regulation of Clinical Software Systems*, Ann. Intern. Med. **127**, 842-845 (1997), describes policy guidelines indicating the

25 desirability of systems that generate advice for clinician users in a manner that users can easily override. Solutions to this need are neither suggested nor disclosed.

M. Pazzani et al., *Application of an Expert System in the Management of HIV-Infected Patients*, J. Acquired Immune Deficiency Syndromes and Human

30

Retrovirology 15, 356-362 (1997) (accepted May 12, 1997), describes a rule-based expert system by which protease, reverse transcriptase, and integrase segments of HIV are cloned and entered into an expert system
5 that recommends two, three, and four drug regimens. A means for easily overriding the advice given is neither suggested nor disclosed.

U.S. Patent No. 5,672,154 to Sillen describes a method for giving patients individualized, situation-
10 dependent medication advice. The recommended type of medicine may include at least two different medicines. No means for ranking multiple treatment options is disclosed, and no means for explaining why treatment options were rejected is given. Rather, this system is
15 primarily concerned with generating new rules from patient information to optimize a particular therapy for diseases such as Parkinson's disease, epilepsy and abnormal blood pressure.

U.S. Patent No. 5,694,950 to McMichael
20 describes a method and system for use in treating a patient with immunosuppressants such as cyclosporin. An expert system is employed to generate a recommendation on whether the immunosuppressant dosage should be changed and, if so, how. Ranking or selection among a
25 plurality of different combination therapeutic treatment regimens is not suggested.

U.S. Patent No. 5,594,638 to Iliff describes a medical diagnostic system that provides medical advice to the general public over a telephone network.
30 This system is not concerned with generating a recommendation for a combination therapeutic treatment

regimen for a known disease (see also U.S. Patent No. 5,660,176 to Iliff).

Summary of the Invention

5 In view of the foregoing, an object of the invention is to provide systems, methods and computer program products for selecting therapeutic treatment regimens for patients in which available treatments are listed, and optionally ranked, while unavailable or
10 rejected treatment regimens (e.g., regimens that would not be effective, or would be dangerous) are not displayed or are assigned a low rank and are indicated to a user as not likely to be efficacious, or not
15 preferred due to patient-specific complicating factors such as drug interaction from concomitant medications.

 A further object of the invention is to provide systems, methods and computer program products for selecting treatment regimens in which the available treatment options can be readily understood.

20 A further object of the invention is to provide systems, methods and computer program products for selecting treatment regimens in which the implications of selecting a particular treatment regimen can be readily understood.

25 A further object of the invention is to provide systems, methods and computer program products for selecting treatment regimens in which the reasons for rejection of a particular regimen can be readily understood.

30 A still further object of the invention is to provide systems, methods and computer program products

for obtaining information about the efficacy of previous treatment regimens imposed on patients.

A method of the present invention includes providing patient information to a computing device that includes various knowledge bases. For example, a first knowledge base may include a plurality of different therapeutic treatment regimens for a disease or medical condition. A second knowledge base may include a plurality of expert rules for selecting a therapeutic treatment regimen for the disease or medical condition. A third knowledge base may include advisory information useful for the treatment of a patient with different constituents of different therapeutic treatment regimens. A fourth knowledge base may include information about past therapies, such as how a patient has fared under previous therapies.

A listing (preferably a ranked listing) of therapeutic treatment regimens for a patient is generated in the computing device. Advisory information for one or more treatment regimens in the listing is generated in the computing device based on the patient information and the expert rules.

In a preferred embodiment, the method described above further includes entering a user-defined therapeutic treatment regimen for the disease (or medical condition) that may not be displayed from the system knowledge base-generated therapeutic treatment regimens, and generating in the computing device advisory information for the user-defined combination therapeutic treatment regimen.

In addition, in a preferred embodiment, the

method described above further includes entering a rejected therapeutic treatment regimen for the disease (or medical condition) that is included in the first knowledge base but not recommended from the ranking (or
5 given a very low ranking), and generating in the computing device advisory information for the non-recommended/low ranked therapeutic treatment regimen, wherein the advisory information includes at least one reason for not recommending (or low ranking) the
10 therapeutic treatment regimen.

Further objects and aspects of the present invention are explained in detail in the drawings herein and the specification set forth below.

15 Brief Description of the Drawings

The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate embodiments of the invention and, together with the description, serve to explain
20 principles of the invention.

Fig. 1 illustrates a process of the instant invention, including routines for entering a user-defined therapeutic treatment regimen and for entering a "non-recommended" therapeutic treatment regimen.

25 **Fig. 2** schematically illustrates a system or apparatus of the present invention.

Fig. 3 illustrates a client-server environment within which the system of **Fig. 2** may operate, according to an embodiment of the present
30 invention, and wherein a central server is accessible by at least one local server via a computer network,

such as the Internet, and wherein each local server is accessible by at least one client.

Fig. 4 illustrates a medical history user interface for entering data about a patient's medical history according to the present invention.

Fig. 5 illustrate a user interface chart for monitoring a patient's condition during a particular therapeutic treatment regimen over a period of time according to the present invention.

Fig. 6 illustrates a therapy evaluation user interface that facilitates evaluation of various therapeutic treatment regimen options with respect to relative efficacy, individualized adjusted relative efficacy, dosage, frequency, cost, medical complications and drug interactions according to the present invention.

Fig. 7 illustrates various symbols for providing information about a therapeutic treatment regimen option within the therapy list box of the therapy evaluation user interface of **Fig. 6** according to the present invention.

Fig. 8 illustrates the therapy details box of **Fig. 6** in "full screen" mode.

Fig. 9 illustrates a pop-up menu including an indexed electronic link to a PDR® that can be activated from within the therapy list box of the therapy evaluation user interface of **Fig. 6** according to the present invention.

Figs. 10A-10D illustrate various functions of the present invention as described in Example 1.

Figs. 11A-11E illustrate various functions of

the present invention as described in Example 2.

Figs. 12A-12C illustrate various functions of the present invention as described in Example 3.

5 Detailed Description of the Invention

 The present invention now will be described more fully hereinafter with reference to the accompanying drawings, in which preferred embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Like numbers refer to like elements throughout.

 As will be appreciated by one of skill in the art, the present invention may be embodied as a method, data processing system, or computer program product. Accordingly, the present invention may take the form of an entirely hardware embodiment, an entirely software embodiment, or an embodiment combining software and hardware aspects. Furthermore, the present invention may take the form of a computer program product on a computer-usable storage medium having computer readable program code means embodied in the medium. Any suitable computer readable medium may be utilized including, but not limited to, hard disks, CD-ROMs, optical storage devices, and magnetic storage devices.

30 The present invention is described below with reference to flowchart illustrations of methods,

apparatus (systems), and computer program products according to an embodiment of the invention. It will be understood that each block of the flowchart illustrations, and combinations of blocks in the flowchart illustrations, can be implemented by computer program instructions. These computer program instructions may be provided to a processor of a general purpose computer, special purpose computer, or other programmable data processing apparatus to produce a machine, such that the instructions, which execute via the processor of the computer or other programmable data processing apparatus, create means for implementing the functions specified in the flowchart block or blocks.

These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including instruction means which implement the function specified in the flowchart block or blocks.

The computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart block or blocks.

A method of the instant invention is illustrated in **Fig. 1**. In the first step **10**, the patient is examined to determine patient information. Examples of patient information that may be gathered
5 include one or more of gender, age, weight, CD4⁺ cell information, viral load information, HIV genotype and phenotype information, hemoglobin information, neuropathy information, neutrophil information, pancreatitis, hepatic function, renal function, drug
10 allergy and intolerance information, and information for drug treatments for other conditions. The information may include historical information on prior therapeutic treatment regimens for the disease or medical condition. While the patient is typically
15 examined on a first visit to determine the patient information, it will be appreciated that patient information may also be stored in the computing device, or transferred to the computing device from another computing device, storage device, or hard copy, when
20 the information has been previously determined.

The patient information is then provided **11** to a computing device that contains a knowledge base of treatments, contains a knowledge base of expert rules for determining available treatment options for the
25 patient in light of the patient information, and also contains a knowledge base of advisory information. A list of available treatments for the patient is then generated **12** from the patient information and the available treatments by the expert rules, and advisory
30 information for the available treatments is generated **13**. The advisory information may include warnings to

take the patient off a contraindicated drug or select a suitable non contraindicated drug to treat the condition before initiating a corresponding treatment regimen and/or information clinically useful to
 5 implement a corresponding therapeutic treatment regimen.

For example, when the known disease is HIV-1 infection, the treatment regimen includes antiretroviral drugs, and the treatment regimen or
 10 advisory information may also include contraindicated or potentially adversely interacting non-antiretroviral drugs. Particularly, when the treatment regimen includes a protease inhibitor. A contraindicated drug may be terfenadine. When the treatment regimen includes
 15 indinavir, a contraindicated drug is cisapride.

Exemplary antiretroviral drugs are listed below in **Table 1**.

Table 1

Abbreviation	Formal Name	Generic Name
ABC	ZIAGEN®	Abacavir
ADV	PREVEON®	Adefovir
APV	AGENERASE®	Amprenavir
AZT	RETROVIR®	Zidovudine
ddI	VIDEX®	Didanosine
ddC	HIVID®	Zalcitabine
d4T	ZERIT®	Stavudine
EFV	SUSTIVA®	Efavirenz
3TC	EPIVIR®	Lamivudine
SQV	INVIRASE®/ FORTOVASE®	Saquinavir
IDV	CRIXIVAN®	Indinavir
RTV	NORVIR®	Ritonavir
DLV	RESCRIPTOR®	Delavirdine
NFV	VIRACEPT®	Nelfinavir
NVP	VIRAMUNE®	Nevirapine

Exemplary advisory information that can be displayed to a user is summarized below in **Table 2**.

Table 2

	Description
Drug Therapies (All the output data types below are associated with a therapy)	The inference engine will process every therapy from a resource file which contains all valid therapy combinations. The system will support multiple drug combinations. Those therapies which are recommended by the knowledge base will be displayed along with all the data types below.
Commentaries	Commentaries consist of warnings and advisories concerning drugs as well as various patient conditions. Each commentary will appear in specific locations of the User Interface. Commentaries will have various Flags, Triggers, and Output Locations.
Rejection Notices	Rejection Notices are the explanation why a given therapy is not recommended. Rejection notices always appear in predefined places in the User Interface.
Cost	The cost per day is calculated for each therapy by the inference engine as well as each drug cost within a therapy.
Dosage	The base dosage and any adjustments to the base dosage due to various patient conditions are calculated by the inference engine.
Pill Burden	The number of pills in the therapy.
Frequency	Number of times the patient will be taking medications for a given therapy. For a multi-drug therapy, the Frequency of the therapy is the drug in the therapy that has the highest number of Frequencies. If a three-drug regimen has 2 drugs with q12h dosages and one that is a q8h, the therapy is considered to be a q8h Frequency.
Admin	Special drug administration instructions.
Efficacy	The relative Efficacy is a whole number that represents the relative efficacy of the various therapies. One is the most effective therapy.
Adjusted Score	The "Adjusted Score" is the Efficacy adjusted up or down based on patient specific characteristics to roughly indicate the likelihood of that therapy being an effective treatment for that patient. An example would be: the system evaluates a therapy containing a drug that is known to be associated with a medical condition in that patient's medical history, therefore the therapy is ranked low. The Ranking Ordinal is an integer, beginning with 0 and

	<p>having no upper limit. A therapy with a 1 Ranking Ordinal (RO=1) would be ranked at the top of the list whereas a therapy with a 10 Ranking Ordinal (RO=10) would be less likely to be successful given the patient's specific history and characteristics. Each therapy will have a starting RO number which will be the therapy's relative efficacy score. The relative efficacy score can then be adjusted up or down by the rules. Both base "Efficacy" number and the "Adjusted Score" number can be displayed.</p>
--	---

Diseases (or medical conditions), the treatment of which may be facilitated or improved by the present invention, are those for which multiple

5 different therapy options are available for selection and treatment. Such diseases and medical conditions include, but are not limited to, cardiovascular disease (including but not limited to congestive heart failure, hypertension, hyperlipidemia and angina), pulmonary

10 disease (including but not limited to chronic obstructive pulmonary disease, asthma, pneumonia, cystic fibrosis, and tuberculosis), neurologic disease (including but not limited to Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis,

15 amyotrophic lateral sclerosis or ALS, psychoses such as schizophrenia and organic brain syndrome, neuroses, including anxiety, depression and bipolar disorder), hepatitis infections (including hepatitis B and hepatitis C infection), urinary tract infections,

20 venereal disease, cancer (including but not limited to breast, lung, prostate, and colon cancer), etc. It should be appreciated that prevention of development or onset of the above-mentioned diseases and medical conditions may be facilitated or improved by the

25 present invention.

The present invention is useful for known diseases such as HIV-1 infection (acquired immune deficiency syndrome or "AIDS"), or where the known disease is any medical condition for which a combination therapeutic treatment regimen can be used. The invention is particularly useful when the list of available treatments includes a plurality (e.g., 2, 10 or 15 or more) of treatment, combination therapeutic treatment regimens (e.g., therapeutic treatment regimens incorporating two or more active therapeutic agents), where the potential for drug interactions is increased and/or the complexity involved in selecting the best available treatment is multifactorial.

Advantageously, the list of available treatments and advisory information may be regenerated in a number of ways. The patient information may be simply modified 18. In addition, if a particular therapy in which the user might be interested is not presented, a user-defined therapy may be entered 14 and advisory information generated 15 based on the user-defined therapy. Still further, if a therapeutic treatment regimen that is in the knowledge base is rejected by the system (not recommended upon display), the non-recommended therapeutic treatment regimen may be entered 16 and advisory information generated 17 for the non-recommended therapeutic treatment regimen. This may indicate to the user that they should discontinue use of a non-critical drug for another condition or select a suitable substitute that does not create a conflict/non-recommended situation so that they can then proceed with the therapy of choice. Alternatively,

the advisory information can be generated automatically for non-recommended therapeutic treatment regimens. These various steps can be repeated in any sequence in an interactive manner to provide the user with
5 assurance that all treatment options have been given adequate and appropriate consideration.

The terms "therapy" and "therapeutic treatment regimen" are interchangeable herein and, as used herein, mean any pharmaceutical or drug therapy,
10 regardless of the route of delivery (e.g., oral, intravenous, intramuscular, subcutaneous, intraarterial, intraperitoneal, intrathecal, etc.), for any disease (including both chronic and acute medical conditions, disorders, and the like). In addition, it
15 is understood that the present invention is not limited to facilitating or improving the treatment of diseases. The present invention may be utilized to facilitate or improve the treatment of patients having various medical conditions, without limitation.

20

System Description

The present invention may be embodied as an expert system that provides decision support to physicians (or other health care providers) treating
25 patients with a known disease, such as HIV infection. A system according to the present invention calculates combination antiretroviral therapy options and attaches all relevant information to those options.

As known to those of skill in the art, an
30 expert system, also known as artificial intelligence (AI), is a computer program that can simulate the

judgment and behavior of a human or an organization that has expert knowledge and experience in a particular field. An expert system typically contains a knowledge base containing accumulated experience and a set of rules for applying the knowledge base to each particular situation that is described to the program. Expert systems are well known to those of skill in the art and need not be described further herein.

The antiretroviral therapy options (combinations of antiretroviral drugs), are derived using a knowledge base consisting of a number of expert system rules and functions which in turn take into account a given patient's treatment history, current condition and laboratory values. A system according to the present invention supports the entry, storage, and analysis of patient data in a large central database. A system according to the present invention has a flexible data driven architecture and custom reporting capabilities designed to support patient therapy management and clinical drug trial activities such as screening, patient tracking and support. It is anticipated that a system according to the present invention may be used by health care providers (including physicians), clinical research scientists, and possibly healthcare organizations seeking to find the most cost-effective treatment options for patients while providing the highest standard of care.

A system 20 for carrying out the present invention is schematically illustrated in Fig. 2. The system 20 comprises a knowledge base of treatment regimens 21, which may be ranked for efficacy (e.g., by

a panel of experts) or ranked according to system rules, a knowledge base of expert rules 22, a knowledge base of advisory information 23, a knowledge base of patient therapy history 24 and patient information 25.

5 Patient information is preferably stored within a database and is configured to be updated. The knowledge bases and patient information 21-25 may be updated by an input/output system 29, which can comprise a keyboard (and/or mouse) and video monitor. Note also
10 that, while the knowledge bases and patient data 21-25 are shown as separate blocks, the knowledge bases and patient data 21-25 can be combined together (e.g., the expert rules and the advisory information can be combined in a single database).

15 To carry out the method described above, the information from blocks 21-25 is provided to an inference engine 26, which generates the listing of available treatments and the corresponding advisory information from the information provided by blocks 21-
20 25. The inference engine 26 may be implemented as hardware, software, or combinations thereof. Inference engines are known and any of a variety thereof may be used to carry out the present invention. Examples include, but are not limited to, those described in
25 U.S. Patents Nos. 5,263,127 to Barabash et al. (Method for fast rule execution of expert systems); 5,720,009 to Kirk et al. (Method of rule execution in an expert system using equivalence classes to group database objects); 5,642,471 to Paillet (Production rule filter
30 mechanism and inference engine for expert system); 5,664,062 to Kim (High performance max-min circuit for

a fuzzy inference engine).

High-speed inference engines are preferred so that the results of data entered are continually updated as new data is entered. As with the knowledge bases and patient information in blocks 21-25, the inference engine 26 may be a separate block from the knowledge bases and patient information blocks 21-25, or may be combined together in a common program or routine.

Note that the advisory information that is generated for any available therapy may differ from instance to instance based on differences in the patient information provided.

System Architecture

The present invention can be implemented as a system running on a stand alone computing device. Preferably, the present invention is implemented as a system in a client-server environment. As is known to those of skill in the art, a client application is the requesting program in a client-server relationship. A server application is a program that awaits and fulfills requests from client programs in the same or other computers. Client-server environments may include public networks, such as the Internet, and private networks often referred to as "intranets", local area networks (LANs) and wide area networks (WANs), virtual private networks (VPNs), frame relay or direct telephone connections. It is understood that a client application or server application, including computers hosting client and server applications, or other

apparatus configured to execute program code embodied within computer usable media, operates as means for performing the various functions and carries out the methods of the various operations of the present invention.

Referring now to **Fig. 3**, a client-server environment 30 according to a preferred embodiment of the present invention is illustrated. The illustrated client-server environment 30 includes a central server 32 that is accessible by at least one local server 34 via a computer network 36, such as the Internet. A variety of computer network transport protocols including, but not limited to TCP/IP, can be utilized for communicating between the central server 32 and the local servers 34.

Central Server

The central server 32 includes a central database 38, such as the Microsoft® SQL Server application program, version 6.5 (available from Microsoft, Inc., Redmond, WA), executing thereon. The central server 32 ensures that the local servers 34 are running the most recent version of a knowledge base. The central server 32 also stores all patient data and performs various administrative functions including adding and deleting local servers and users to the system (20, **Fig. 2**). The central server 32 also provides authorization before a local server 34 can be utilized by a user. Patient data is preferably stored on the central server 32, thereby providing a central repository of patient data. However, it is understood

that patient data can be stored on a local server 34 or on local storage media.

Local Server

5 Each local server 34 typically serves multiple users in a geographical location. Each local server 34 includes a server application, an inference engine, one or more knowledge bases, and a local database 39. Each local server 34 performs artificial
10 intelligence processing for carrying out operations of the present invention. When a user logs on to a local server 34 via a client 35, the user is preferably authenticated via an identification and password, as would be understood by those skilled in the art. Once
15 authenticated, a user is permitted access to the system (20, Fig. 2) and certain administrative privileges are assigned to the user.

Each local server 34 also communicates with the central server 32 to verify that the most up-to-
20 date version of the knowledge base(s) and application are running on the requesting local server 34. If not, the requesting local server 34 downloads from the central server 32 the latest validated knowledge base(s) and/or application before a user session is
25 established. Once a user has logged onto the system (20, Fig. 2) and has established a user session, all data and artificial intelligence processing is preferably performed on a local server 34. An advantage of the illustrated client-server configuration is that
30 most of the computationally intensive work occurs on a local server 34, thereby allowing "thin" clients 35

(i.e., computing devices having minimal hardware) and optimizing system speed.

In a preferred embodiment, each local server database 39 is implemented via a Microsoft® SQL Server application program, Version 6.5. The primary purpose of each local database 39 is to store various patient identifiers and to ensure secure and authorized access to the system (20, Fig. 2) by a user. It is to be understood, however, that both central and local databases 38, 39 may be hosted on the central server 32.

Local Client

Each local client 35 also includes a client application program that consists of a graphical user interface (GUI) and a middle layer program that communicates with a local server 34. Program code for the client application program may execute entirely on a local client 35, or it may execute partly on a local client 35 and partly on a local server 34. As will be described below, a user interacts with the system (20, Fig. 2) by entering (or accessing) patient data within a GUI displayed within the client 35. The client 35 then communicates with a local server 34 for analysis of the displayed patient information.

Computer program code for carrying out operations of the present invention is preferably written in an object oriented programming language such as JAVA®, Smalltalk, or C++. However, the computer program code for carrying out operations of the present invention may also be written in conventional

procedural programming languages, such as the "C"
programming language, in an interpreted scripting
language, such as Perl, or in a functional (or fourth
generation) programming language such as Lisp, SML, or
5 Forth.

The middle layer program of the client
application includes an inference engine within a local
server 34 that provides continuous on-line direction to
users, and can instantly warn a user when a patient is
10 assigned drugs or a medical condition that is
contraindicated with, or antagonistic of, the patient's
current antiretroviral therapy. Every time patient data
is entered into the system (20, Fig. 2) or updated, or
even as time passes, the inference engine evaluates the
15 current status of the patient data, sorting,
categorizing, ranking and customizing every possible
antiretroviral therapy for a patient according to the
specific needs of the patient.

20 Inference Engine

Inference engines are well known by those of
skill in the art and need not be described further
herein. Each knowledge base used by an inference engine
according to the present invention is a collection of
25 rules and methods authored by a clinical advisory panel
of HIV-treating physicians and scientists. A knowledge
base may have subjective rules, objective rules, and
system-generated rules. Objective rules are based on
industry established facts regarding the treatment of
30 HIV using antiretroviral therapy and are drawn from the
package insert information of antiretroviral drug

manufacturers and from peer reviewed and published journal articles. An example of an objective rule would be an antiretroviral to antiretroviral contraindication such as:

5

Rule #1: If the eval therapy contains Zidovudine (AZT) and Stavudine (d4T), then reject the therapy.

10 In Rule #1, the term "eval therapy" refers to the therapy currently being analyzed by the system (20, **Fig. 2**). Rule #1 then states that if this therapy contains both AZT and d4T, then this therapy should not be displayed in a list of potential therapy options for
15 the patient.

For objective rules, the present invention can be configured so as to prevent a user from receiving recommendations on new therapy options when certain crucial data on the patient has not been
20 entered. However, it is understood that the present invention does not prevent a health care provider, such as a physician, from recording his/her therapy decisions, even if the system (20, **Fig. 2**) has shown reasons why that therapy may be harmful to the patient.
25 The present invention allows a health care provider to be the final authority regarding patient therapy.

Subjective rules are based on expert opinions, observations and experience. Subjective rules are typically developed from "best practices"
30 information based on consensus opinion of experts in the field. Such expert opinion may be based on knowledge of the literature published or presented in

the field or their own experience from clinical practice, research or clinical trials of approved and unapproved medications. A number of experts are used so that personal bias is reduced.

5 System generated rules are those derived from the outcomes of patients tracked in the system who received known and defined therapies and either improved, stabilized or worsened during a defined period. Because of the large number of potential
10 combinations usable in HIV infection, this system generated database and rules derived from them are likely to encompass data beyond that achievable from objective or subjective rules databases.

 The rules which comprise the various
15 knowledge bases (21-24, Fig. 2) of the present invention each have two main parts: a premise and a conclusion - also referred to as the left side and the right side, respectively. When a premise of a rule is found to be true, the action specified in the
20 conclusion is taken. This is known to those of skill in the art as "firing" the rule. For example, consider the following rule:

Rule ID	Premise	Conclusion
25 FiltDComA1	-- If the eval therapy contains ddC	- Commentary 18

The premise of the above rule is for the inference engine to determine whether or not a therapy being evaluated (i.e., "eval therapy") contains the
30 antiretroviral drug "ddC". If a therapy does contain the antiretroviral drug ddC, the action called for by the conclusion of the rule is to attach "Commentary 18"

to the therapy. Commentary 18 may be a piece of text that provides a user with the necessary information about therapies containing ddC.

Exemplary rules which may comprise one or more knowledge bases according to the present invention are listed below in **Table 3**.

Table 3

Therapy initiation/change: Rules that provide information on therapy change or initiation
Boundary condition rules: Limits for values, intervals for values to be updated
Comment Data Aging rules: These rules warn the user that the data in certain fields is getting old and that the most current values in the system will be used.
Rules that filter therapies due to drug interactions in ARV drug combinations
Rules that filter therapies due to medical conditions
Rules that filter therapies due to genotypic mutations in patient's plasma HIV
Rules that filter therapies due to phenotypic sensitivity/resistance
Antiretroviral therapy ranking rules
General dosage rules
Solid dosage rule
Dosage modifications due to ARV-ARV drug combination
Dosage modification due to ARV-NonARV interaction
Dosage modification due to medical condition
Comment determined
General commentary rules
Commentaries added due to medical conditions
Commentaries added due to drug interactions

Commentaries added due to drug combination
Delivery size rules

Using the various knowledge bases and patient information of the present invention (21-25, **Fig. 2**), the inference engine (26, **Fig. 2**) can evaluate potential therapy options for a patient based on a patient's medical history (including therapy history) and current laboratory values. Accordingly multiple antiretroviral drug combinations can be quickly and accurately analyzed for a particular patient.

Furthermore, the inference engine can quickly provide guidance in the areas listed below in **Table 4**.

Table 4

Data Integrity	Is the patient lab and assessment data getting too old to be considered reliable? Are there conflicts between lab data such as phenotype data which indicates resistance to one or more antiretroviral drugs in the patient's current therapy and current viral load data which indicates significant viral suppression?
Therapy Performance	Should antiretroviral therapy be initiated for the patient? Is the patient's current therapy achieving good initial and long-term viral suppression or should the therapy be changed? Are there potential non-compliance issues as demonstrated by a lack of viral suppression with a regimen when current genotype or phenotype data does provide explanation for the failure by demonstrating resistance to any drugs in the patient current therapy?
Dosage	What are the base and adjusted dosages of antiretroviral drugs in a given therapy? Are there any special specific dosage administration instructions? What are options if patient can only take liquid dosage forms?
Contra-indications	Which antiretroviral drugs can be used with each other and what dosage adjustments are

	required? Are there any contraindications or interactions between antiretroviral drugs in patient's current therapy or potential therapies and the non-antiretroviral drugs patient is taking and if so what are they and what, if any, dosage adjustments are required?
Medical Conditions	Are there any medical conditions to be aware of in deciding an appropriate therapy for patient? What, if any, effect do current or historical medical conditions have on each therapy option?
Drug Cost and Delivery Data	How much does each therapy option cost? What is the dosing frequency of the drugs in the therapy? What is the pill count and optimum delivery size for the least number of pills?
Therapy Options	What are all the drug combination therapy options for patient? How can physician instantly assess which of the hundreds of potential combinations will be the most effective for patient? What information from the package inserts from each drug apply specifically to patient? What is the relative antiviral efficacy of each therapy? Are there special considerations that might make one therapy more or effective for patient?
Resistance	What drugs are patient's virus current genotypic or phenotypic profile known to be associated with resistance to? Which antiretroviral drugs are more effective against resistant strains when used together? Which drugs (if any) used in historical therapies are most likely to be effective if recycled into a new therapy? Can any of the drugs in patient's current therapy be recycled into the next therapy?

User Interface

Referring now to **Figs. 4-9**, exemplary user interfaces according to the present invention will be illustrated. In **Fig. 4**, a medical history user interface 50 for entering data about a patient's medical history according to the present invention is

illustrated. The medical history user interface 50 can be displayed by activating the "Medical History" tab 50a. The illustrated medical history user interface 50 allows a user to create, save, update and print patient records. When a user adds a new patient, the medical history user interface 50 appears with empty data entry fields. Data entry fields for receiving information via a GUI are well known to those of skill in the art and need not be described further herein. When a user opens a patient record for editing, the medical history user interface 50 appears with patient data in the various fields. Preferably color is used to highlight critical or required information in a patient record.

Important elements in the illustrated medical history user interface 50 include a "print" button 51 for printing a patient record and therapeutic treatment regimen details; a "save" button 52 for saving a patient record; and a "speed entry" check box 53 for allowing a user to move quickly between entry fields. In addition, there are multiple group headings 54 that divide a patient's medical history into related categories. Each group contains entry fields in which a user can add patient information. An "add" button 55 allows a user to add new information to a patient record for a selected group. A "delete" button 56 allows a user to delete patient information for a selected group (although the original information is still recorded in the database). A "history" button 57 allows a user to review a patient's historical data for each selected group.

After completing a patient's medical history,

an inference engine analyzes the data and suggests whether a therapeutic treatment regimen is indicated; if an existing therapeutic treatment regimen should be continued or changed; and the best drug therapies for the selected patient. Often, more than one drug therapy is presented to the user. These drug therapies are preferably ranked according to expected efficacy, frequency in dosage, pill count, and cost. All of these factors can help the user make a decision about what therapy to use for the selected patient. When a user clicks on a drug therapy in the presented list, information is provided about the dosage regimens. Also, various warnings, such as drug interaction warnings, and notes about each drug, are presented. An appropriate drug therapy can then be selected.

In **Fig. 5**, an exemplary user interface chart 60 for monitoring a patient's condition during a particular drug therapy over a period of time is illustrated. The user interface chart 60 can be displayed by activating the "Chart" tab 60a. The illustrated user interface chart 60 tracks the CD4 level against viral load. Along the left-hand side of the Y-axis 61 the CD4 count is plotted. Along the right-hand side of the Y-axis 61 the viral load count is plotted. The lines 62 represent the CD4 test and the viral load test as would be understood by those having skill in the art. Drug therapy for a time period is indicated within the area of the chart user interface 60 indicated as 63. Time is plotted along the X-axis 64, as illustrated.

In **Fig. 6**, a therapy evaluation user

interface 70 that facilitates evaluation of various therapy options with respect to relative efficacy, dosage, frequency, cost, medical complications and drug interactions is illustrated. The therapy evaluation user interface 70 can be displayed by activating the "Therapy Evaluation" tab 70a. Important elements in the illustrated therapy evaluation user interface 70 include an "Evaluate Current Therapy" button 71 for initiating an evaluation of a current therapy and a "Current Therapy" field 72 that lists a patient's current therapy. Detailed information about a patient's therapy is displayed in the therapy details box 73. A therapy displayed within box 73 is identified in box 74.

Multiple check boxes 75 are provided that allow a user to control how information is displayed within the therapy evaluation user interface 70. Within the therapy list box 76, a list of available therapies for a patient can be displayed. In the illustrated embodiment the drugs are listed in standard abbreviated form. Other information displayed with each drug may include that listed below in Table 5.

Table 5

Efficacy Rating	Lists the therapy according to expected effectiveness only, regardless of patient specific considerations (1 is most effective).
Adjusted Score	This number uses the Efficacy Rating as a base and then the system adjusts it up or down based on patient specific conditions (1 is most effective).
Safety Considerations	A brief two or three word summary of the alerts associated with the therapy.
Frequency	Lists the dosage frequency (q12h, q24h, etc.).
Pills	Lists the total number of pills required per day for

	the complete regimen.
Cost	Lists the total cost of the regimen per day.
Medical Alert	Displays a Y if there is one or more Yellow Medical Alerts and an R if there is one or more Red Medical Alerts associated with the therapy.
Drug Interaction	Displays a Y if there is one or more Yellow Drug Interaction Alerts and an R if there is one or more Red Drug Interaction Alerts associated with the therapy.

A list of available antiretroviral drugs is displayed within box 77. A user desiring to evaluate a particular combination of drugs can click the appropriate check boxes 77a to review information in the therapy details box 73. A "Use as Current Therapy" button 78 allows a user to apply a particular therapy to a patient. Various hyperlinks 79 within the therapy details box 73 allow a user to display specific information about a therapy evaluation. For example, a user can be allowed to view a rule which is associated with the displayed text.

Resistance evaluation alerts 80 can be provided adjacent each available antiretroviral drug displayed within box 77. For example, a blue "G" icon can be used to indicate that a patient's last genotype test contains mutations which are known to be associated with full or partial resistance to the antiretroviral drug. A red "P" icon can be used to indicate that a patient's last phenotype test demonstrates resistance to the antiretroviral drug.

Within the therapy list box 76, various symbols (described in Fig. 7) can be utilized to provide information about a drug therapy option. These symbols provide an instant graphical warning level for

each therapy option. Some symbols, such as a red exclamation point, indicate that there is critical, possibly life threatening information in the therapy details box 73 for that therapy which must be read in order for that therapy to be properly utilized.

When a drug therapy from the therapy list box 76 is selected by a user for evaluation, the therapy details box 73 of Fig. 6 can be displayed in "full screen" mode as illustrated in Fig. 8. Important elements in the illustrated therapy details box 73 include an identification box 73a for identifying the therapy being evaluated; a "Use as Current Therapy" button 78 that allows a user to apply a particular therapy to a patient; and a "Show Therapies" button 73b that returns the therapy details box 73 back to half-screen size as illustrated in Fig. 6. In addition, various hyperlinks may be embedded within text displayed within the therapy details box 73 that can be activated by a user to display various types of information. Eye catching alert banner(s) 73c and text 73d can be displayed at the top of the therapy details box 73 as illustrated. Dosages 73e of each drug, along with special administration instructions, can be displayed within the therapy details box 73 as illustrated. Dosage adjustment information 73f and various warnings and advisories 73g can also be displayed within the therapy details box 73 as illustrated.

According to a preferred embodiment of the present invention, therapeutic treatment regimens are not displayed to a user if an invalid drug is selected

for treatment of a patient.

Physicians Desk Reference®

According to a preferred embodiment of the present invention, the Physicians Desk Reference® (PDR®) 28, which is a known drug reference source, is fully integrated with the system 20 of **Fig. 2**. Users can access the PDR® drug abstracts for antiretroviral drugs listed in the therapy list box 76 of the therapy evaluation user interface 70 of **Fig. 6**. In addition, users can access the PDR® on-line Web database to obtain additional information about a specific drug or to research a substitute for a contraindicated drug. When a user selects a drug within the therapy list box 76 of the therapy evaluation user interface 70, a web browser preferably is launched and the PDR® on-line Web database is accessed. Information can also be extracted from the PDR® on-line Web database to provide drug selection lists for non-antiretroviral drugs that a patient may be taking and to define relationships between brand name and generic drugs.

As illustrated in **Fig. 9**, a PDR® pop-up menu 90 may be provided that can be activated from within the therapy list box 76 of the therapy evaluation user interface 70 of **Fig. 6**. From the PDR® pop-up menu 90 a user can access various information from the PDR® including, but not limited to, drug abstracts, and generic components contained within a brand name drug.

The following non-limiting examples illustrate various aspects of the present invention. These examples are provided for illustrative purposes

only, and are not intended to be limiting of the invention.

EXAMPLE 1

5 Example 1 will be explained with reference to
Figs. 10A-10D. Referring to **Fig. 10A**, a medical history
user interface **50** containing evaluated data for patient
"demo1" is illustrated. The group heading "Hemoglobin"
10 **54a** has changed colors to indicate to a user that the
patient has an abnormally low hemoglobin value from a
previous (historical) blood sampling. When the therapy
evaluation tab **70a** is activated to display the therapy
evaluation user interface **70** (**Fig. 10B**) the associated
15 medical condition warning of a history of anemia and
the caution notification if using drugs known to be
associated with hematopoietic toxicity is triggered as
illustrated in the therapy details box **73** of **Fig. 10B**.

 In addition, the group heading "Renal
Function" **54b** in **Fig. 10A** has changed colors to warn a
20 user of potential renal dysfunction and is also
indicated by the low estimated creatinine clearance
rate in field **F1** (which the system calculates using a
mathematical formula taking patient age, sex, weight,
and serum creatinine values - all of which are fields
25 of the "Medical History" user interface **50**). This
information is pointed out to the user and is used if
dosage adjustments are required for drugs that are
known to be affected (cleared) by renal function.

 Current and the next most recent CD4⁺ cell
30 count and viral load are displayed (**F2**, medical history
user interface **50**). This information is also used to

determine when to start or change therapy and to evaluate the initial antiviral efficacy of a newly administered antiviral regimen.

Current and historical values for all fields
5 in the medical history user interface 50 (Fig. 10A) can be viewed by pressing the "H" button beside fields that have this button.

In Fig. 10C, the "Chart" user interface 60
has been activated. HIV RNA (viral load) is plotted on
10 a log scale, the CD4 count is plotted on a linear scale, and the drug treatments are shown as Gantt bars on the horizontal date scale at the bottom of the chart user interface 60.

In Fig. 10D, the "Change Therapy
15 Recommendation" message box MB1 pops up when the "Therapy Evaluation" tab 70a is selected. This box represents the processing of the data from the "Medical History" tab and the knowledge base output, including objective rules derived from published treatment
20 guidelines, indicating that initiation of therapy, or a change of therapy in this case, may be called for if the other variable(s) indicated in the message have been addressed.

The list of available therapies and
25 associated ranking order may be shown within the therapy details box 73 of Fig. 10B. This represents the output of the knowledge base for therapy selection. Included with the list of therapies can be any of the following: safety advisories (dosage adjustment, drug
30 interaction, etc.) with a yellow triangle or red exclamation warning symbols; number of pills; daily

cost of all three drugs; dosing regimen (q 8h, q 12 h, etc.); and dosages for all drugs in a regimen (including dosage adjustments if necessary) and pertinent information specific to the patient is listed
5 in the dialog box.

EXAMPLE 2

Example 2 will be explained with reference to **Figs. 11A-11E**, and relates to patient file "ARV naive1" which is an example of an HIV-infected patient who has
10 not been treated with anti-HIV drugs previously. In **Fig. 11A**, a medical history user interface 50 containing evaluated data for patient "ARV naive1" is illustrated. In **Fig. 11B**, when the "Therapy Evaluation" tab 70a is activated to display the therapy evaluation
15 user interface 70, a "Boundary and Prequalification Messages" message box MB2 pops up indicating that according to the current, published, HIV treatment guidelines, the patient should be initiated on
20 antiviral therapy and that the current guidelines recommend combinational therapy.

In **Fig. 11C**, the therapy evaluation user interface 70 has been activated and demonstrates features/functions associated with therapy evaluation
25 including a general warning W1 and advisories A1, A2, and A3 for the patient related to treatment of the disease (e.g., whether therapy should be initiated or changed) or related to a specific therapy selected from the list box which is being evaluated by the user.

30 **Fig. 11D** illustrates various information that is displayable by clicking on an individual therapy in

the therapy list box 76 of **Fig. 11C**. Information displayed includes dosages of all drugs with general and patient-specific warnings and advisories.

5 The features available by right clicking on any therapy listed in the therapy list box 76 of **Fig. 11C** are illustrated in **Fig. 11E** and include: linking to an electronic PDR® to show drug package insert information or perform drug search information; showing or hiding columns of information displayed within the
10 therapy list box; linking to a publication or abstract associated with a therapy that has a "book" icon associated therewith; and various printing functions.

EXAMPLE 3

15 Example 3 will be explained with reference to **Figs. 12A-12C**, and relates to patient file "Features1" which illustrates some important functions/features that a system according to the present invention can provide for highly drug experienced patients who may
20 have developed resistance associated with the use of several antiviral drugs. Features, including functions attributed to the new resistance and historical therapy rules are illustrated and includes:

- 25 1) Potential drug resistance advisories (**A1, Fig. 12A**) when the chart tab 60a is activated, or (**A2, Fig. 12B**) when the therapy evaluation tab 70a is activated;
- 30 2) The heads up "P" and "G" indicators (**I1 and I2, Fig. 12B**) to remind of phenotypic or genotypic resistance associated with certain anti-HIV compounds as

demonstrated for this patient (including indication of expected/anticipated genotypic resistance, as a result of cross-resistance, to a drug that a patient may not be taking currently or has not previously taken);

5

3) The drug interaction warning system (indicated by warning W3, Fig. 12C). Warning W3 is for the interaction between Nevirapine and rifabutin (which was selected from the list of non-antiretroviral drugs available as part of the medical history user interface 50). The drug interaction warning message may be viewed from the medical history user interface 50 by "right-clicking" the non-ARV title bar 54C, which has turned yellow indicating the presence of an ARV-nonARV drug interaction. This information is also prominently displayed for the user on the therapy evaluation user interface 70 as a text message (W3, Fig. 12B) as well as in the "Safety Considerations" section of the drug list box (76, Fig. 12B); and

20

4) The chart user interface 60 (Fig. 12A) illustrates the viral load, CD4, drug therapies, and associated drug resistance in graphic form for the user to evaluate.

25

The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. Although a few exemplary embodiments of this invention have been described, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and

30

advantages of this invention. Accordingly, all such modifications are intended to be included within the scope of this invention as defined in the claims.

Therefore, it is to be understood that the foregoing is
5 illustrative of the present invention and is not to be construed as limited to the specific embodiments disclosed, and that modifications to the disclosed embodiments, as well as other embodiments, are intended to be included within the scope of the appended claims.
10 The invention is defined by the following claims, with equivalents of the claims to be included therein.

THAT WHICH IS CLAIMED IS:

1. A method for guiding the selection of a therapeutic treatment regimen for a patient with a known disease or medical condition, said method comprising:

5 (a) providing patient information to a computing device comprising:

a first knowledge base comprising a plurality of different therapeutic treatment regimens for said disease or medical
10 condition;

a second knowledge base comprising a plurality of expert rules for evaluating and selecting a therapeutic treatment regimen for said disease or medical condition;

15 a third knowledge base comprising advisory information useful for the treatment of a patient with different constituents of said different therapeutic treatment regimens; and

20 (b) generating in said computing device a listing of available therapeutic treatment regimens for said patient; and

(c) generating in said computing device advisory information for one or more therapeutic
25 treatment regimens in said listing based on said patient information and said expert rules.

2. A method according to claim 1, further

comprising the steps of:

(d) entering a user-defined therapeutic
treatment regimen for said disease or medical condition
5 that is not included in said first knowledge base;

(e) generating in said computing device
advisory information for said user-defined combination
therapeutic treatment regimen.

3. A method according to claim 1, further
comprising the steps of:

(f) entering a non-recommended therapeutic
treatment regimen for said disease or medical condition
5 that is included in said first knowledge base but not
recommended from said listing; and

(g) generating in said computing device
advisory information for said non-recommended
therapeutic treatment regimen, said advisory
10 information including at least one reason for non-
recommendation of said therapeutic treatment regimen.

4. A method according to claim 1, said
patient information comprising gender, age, weight, CD4
information, viral load information, HIV genotype and
phenotype information, hemoglobin information,
5 neuropathy information, neutrophil information,
pancreatitis, hepatic function, renal function, drug
allergy and intolerance information, and information
for drug treatments for other conditions.

5. A method according to claim 1, said
patient information including prior therapeutic
treatment regimen information.

6. A method according to claim 1, wherein
said listing of available therapeutic treatment
regimens for said patient comprises a ranked listing of
available therapeutic treatment regimens for said
5 patient.

7. A method according to claim 1, wherein
said patient information includes prior patient
information stored in said computing device.

8. A method according to claim 1, said
advisory information including:

warnings to take the patient off a
contraindicated drug before initiating a corresponding
5 therapeutic treatment regimen; and

information clinically useful to implement a
corresponding therapeutic treatment regimen.

9. A method according to claim 1, wherein
said computing device comprises a fourth knowledge base
comprising patient therapeutic treatment regimen
history, said advisory information including previous
5 therapeutic treatment regimen information extracted
from said fourth knowledge base.

10. A method according to claim 8, wherein
said known disease or medical condition is HIV-1
infection, said therapeutic treatment regimen includes
antiretroviral drugs, and said therapeutic treatment
5 regimen includes contraindicated or potentially
adversely interacting non-antiretroviral drugs.

11. A method according to claim 8, wherein said therapeutic treatment regimen includes a protease inhibitor, and said contraindicated drug is terfenadine.

12. A method according to claim 8, wherein said therapeutic treatment regimen includes indinavir and said contraindicated drug is cisapride.

13. A method according to claim 1, wherein said known disease or medical condition is one where multiple prophylactic or therapeutic treatment regimens are available to be used singly or in combination in
5 the treatment of said disease.

14. A method according to claim 1, wherein said known disease or medical condition is a cardiovascular disease.

15. A method according to claim 1, wherein said known disease or medical condition is a pulmonary disease.

16. A method according to claim 1, wherein said known disease or medical condition is a neurologic disease.

17. A method according to claim 1, wherein said known disease or medical condition is cancer.

18. A method according to claim 1, wherein said known disease or medical condition is a urinary

tract infection.

19. A method according to claim 1, wherein said known disease or medical condition is hepatitis.

20. A method according to claim 1, wherein said known disease or medical condition is HIV-1 infection.

21. A method according to claim 1, wherein said knowledge base comprises a plurality of different combination therapeutic treatment regimens.

22. A method according to claim 1, wherein drug dosage information is recommended and adjusted if necessary depending upon said patient information.

23. A method according to claim 1, further comprising the step of:

(d) accessing, via said computing device, information for one or more therapeutic treatment regimens from a drug reference source.

24. A system for guiding the selection of a therapeutic treatment regimen for a patient with a known disease or medical condition, said system comprising:

- 5 (a) a computing device comprising:
a first knowledge base comprising a plurality of different therapeutic treatment regimens for said disease or medical condition;

- 10 a second knowledge base comprising a
 plurality of expert rules for selecting a
 therapeutic treatment regimen for said
 disease or medical condition;
- a third knowledge base comprising
15 advisory information useful for the treatment
 of a patient with different constituents of
 said different therapeutic treatment
 regimens; and
- (b) means for providing patient information
20 to said computing device;
- (c) means for generating in said computing
 device a listing of therapeutic treatment regimens for
 said patient; and
- (d) means for generating in said computing
25 device advisory information for one or more therapeutic
 treatment regimens in said listing based on said
 patient information and said expert rules.

25. A system according to claim 24, further
comprising:

- (e) means for entering a user-defined
 therapeutic treatment regimen for said disease or
5 medical condition that is not generated or displayed
 via said first knowledge base;
- (f) means for generating in said computing
 device advisory information for said user-defined
 combination therapeutic treatment regimen.

26. A system according to claim 24, further
comprising:

- (f) means for entering a non-recommended

therapeutic treatment regimen for said disease or
5 medical condition that is included in said first
knowledge base but not recommended from said listing;
and

(g) means for generating in said computing
device advisory information for said non-recommended
10 therapeutic treatment regimen, said advisory
information including at least one reason for non-
recommendation of said therapeutic treatment regimen.

27. A system according to claim 24, said
patient information comprising gender, age, weight, CD4
information, viral load information, HIV genotype and
phenotype information, hemoglobin information,
5 neuropathy information, neutrophil information,
pancreatitis, hepatic function, renal function, drug
allergy and intolerance information, and information
for drug treatments for other conditions.

28. A system according to claim 24, said
patient information including prior therapeutic
treatment regimen information.

29. A system according to claim 24, wherein
said listing of available therapeutic treatment
regimens for said patient comprises a ranked listing of
available therapeutic treatment regimens for said
5 patient.

30. A system according to claim 24, wherein
said patient information includes prior patient
information stored in said computing device.

31. A system according to claim 24, said advisory information including:

warnings to take the patient off a contraindicated drug before initiating a corresponding therapeutic treatment regimen; and
5 information clinically useful to implement a corresponding therapeutic treatment regimen.

32. A system according to claim 24, wherein said computing device comprises a fourth knowledge base comprising patient therapeutic treatment regimen history, said advisory information including previous
5 therapeutic treatment regimen information extracted from said fourth knowledge base.

33. A system according to claim 31, wherein said known disease or medical condition is HIV-1 infection, said therapeutic treatment regimen includes antiretroviral drugs, and said therapeutic treatment
5 regimen includes contraindicated or potentially adversely interacting non-antiretroviral drugs.

34. A system according to claim 31, wherein said therapeutic treatment regimen includes a protease inhibitor, and said contraindicated drug is terfenadine.

35. A system according to claim 31, wherein said therapeutic treatment regimen includes indinavir and said contraindicated drug is cisapride.

36. A system according to claim 24, wherein

said known disease or medical condition is one where multiple prophylactic therapeutic treatment regimens are available to be used singly or in combination in
5 the treatment of said disease or medical condition.

37. A system according to claim 24, wherein said known disease or medical condition is a cardiovascular disease.

38. A system according to claim 24, wherein said known disease or medical condition is a pulmonary disease.

39. A system according to claim 24, wherein said known disease or medical condition is a neurologic disease.

40. A system according to claim 24, wherein said known disease or medical condition is cancer.

41. A system according to claim 24, wherein said known disease or medical condition is a urinary tract infection.

42. A system according to claim 24, wherein said known disease or medical condition is hepatitis.

43. A system according to claim 24, wherein said known disease or medical condition is HIV-1 infection.

44. A system according to claim 24, wherein

said knowledge base comprises a plurality of different combination therapeutic treatment regimens.

45. A system according to claim 24, wherein drug dosage information is recommended and adjusted if necessary depending upon said patient information.

46. A system according to claim 24, further comprising:

(e) means for accessing, via said computing device, information for one or more therapeutic treatment regimens from a standard drug reference source.

47. A computer program product for guiding the selection of a therapeutic treatment regimen for a patient with a known disease or medical condition, said computer program product comprising a computer usable
5 storage medium having computer readable program code means embodied in the medium, the computer readable program code means comprising:

(a) computer readable program code means for generating a computing device comprising:

10 a first knowledge base comprising a plurality of different therapeutic treatment regimens for said disease or medical condition;

15 a second knowledge base comprising a plurality of expert rules for selecting a therapeutic treatment regimen for said disease or medical condition;

a third knowledge base comprising

20 advisory information useful for the treatment
of a patient with different constituents of
said different therapeutic treatment
regimens; and

(b) computer readable program code means for
providing patient information to said computing device;

25 (c) computer readable program code means for
generating in said computing device a listing of
available therapeutic treatment regimens for said
patient; and

30 (d) computer readable program code means for
generating in said computing device advisory
information for one or more therapeutic treatment
regimens in said listing based on said patient
information and said expert rules.

48. A computer program product according to
claim 47, further comprising:

5 (e) computer readable program code means for
entering a user-defined therapeutic treatment regimen
for said disease or medical condition that is not
generated or displayed via said first knowledge base;

(f) computer readable program code means for
generating in said computing device advisory
information for said user-defined combination
10 therapeutic treatment regimen.

49. A computer program product according to
claim 48, further comprising:

5 (g) computer readable program code means for
entering a non-recommended therapeutic treatment
regimen for said disease or medical condition that is

included in said first knowledge base but not recommended from said listing; and

(h) computer readable program code means for generating in said computing device advisory
10 information for said non-recommended therapeutic treatment regimen, said advisory information including at least one reason for non-recommendation of said therapeutic treatment regimen.

50. A computer program product according to claim 47, said patient information comprising gender, age, weight, CD4 information, viral load information, HIV genotype and phenotype information, hemoglobin
5 information, neuropathy information, neutrophil information, pancreatitis, hepatic function, renal function, drug allergy and intolerance information, and information for drug treatments for other conditions.

51. A computer program product according to claim 47, said patient information including prior therapeutic treatment regimen information.

52. A computer program product according to claim 47, wherein said patient information includes prior patient information stored in said computing device.

53. A computer program product according to claim 47, said advisory information including:

warnings to take the patient off a contraindicated drug before initiating a corresponding
5 therapeutic treatment regimen; and

information clinically useful to implement a corresponding therapeutic treatment regimen.

54. A computer program product according to claim 47 wherein said computing device comprises a fourth knowledge base comprising patient therapeutic treatment regimen history, said advisory information
5 including previous therapeutic treatment regimen information extracted from said fourth knowledge base.

55. A computer program product according to claim 53, wherein said known disease or medical condition is HIV-1 infection, said therapeutic treatment regimen includes antiretroviral drugs, and
5 said therapeutic treatment regimen includes contraindicated or potentially adversely interacting non-antiretroviral drugs.

56. A computer program product according to claim 53, wherein said therapeutic treatment regimen includes a protease inhibitor, and said contraindicated drug is terfenadine.

57. A computer program product according to claim 53, wherein said therapeutic treatment regimen includes indinavir and said contraindicated drug is cisapride.

58. A computer program product according to claim 47, wherein said known disease or medical condition is one where multiple prophylactic therapeutic treatment regimens are available to be used

5 singly or in combination in the treatment of said disease or medical condition.

59. A computer program product according to claim 47, wherein said known disease or medical condition is a cardiovascular disease.

60. A computer program product according to claim 47, wherein said known disease or medical condition is a pulmonary disease.

61. A computer program product according to claim 47, wherein said known disease or medical condition is a neurologic disease.

62. A computer program product according to claim 47, wherein said known disease or medical condition is cancer.

63. A computer program product according to claim 47, wherein said known disease or medical condition is a urinary tract infection.

64. A computer program product according to claim 47, wherein said known disease or medical condition is hepatitis.

65. A computer program product according to claim 47, wherein said known disease or medical condition is HIV-1 infection.

66. A computer program product according to

claim 47, wherein said knowledge base comprises a plurality of different combination therapeutic treatment regimens.

67. A computer program product according to claim 47, wherein drug dosage information is recommended and adjusted if necessary depending upon said patient information.

68. A computer program product according to claim 47, further comprising:

(e) computer readable program code means for accessing, via said computing device, information for
5 one or more therapeutic treatment regimens from a standard drug reference source.

69. A computer program product according to claim 47, wherein said listing of available therapeutic treatment regimens for said patient is a ranked listing of available therapeutic treatment regimens for said patient.

1/22






FIG. 1.



3/22

**FIG. 3.**

4/22

[illegible]

FIG. 4.

5/22




FIG. 5.

71 60a 72 70a 75 70

TPMS Patient Medical History Chart Therapy Evaluation

Evaluate Current Therapy? [AZT, 3TC, IDV]

Show 1-Drug Therapies ☐ Show 2-Drug Therapies ☐ Show 3-Drug Therapies ☒ Show 4-Drug Therapies ☐ Show Rejected Therapies ☐ Show EAP Therapies ☐

Therapy Options (10 of 17)

Therapy	El	Ad	Safety Considerations	Med	Drug	Freq	Pills	Cost
△ ddI, d4T, NFV	2	2	ddI Renal dos. ad, d4T Renal dos. ad	Y		qdh	15	\$30.38
△ ddI, d4T, IDV	3	6	ddI Renal dos. ad, d4T Renal dos. ad	Y		qdh	12	\$26.80
△ ddI, d4T, RTV	4	7	ddI Renal dos. ad, d4T Renal dos. ad	Y		qdh	18	\$34.06
△ d4T, SQV-SGC, NFV	5	8	d4T Renal dos. ad	Y		qdh	29	\$45.60
△ ddC, SQV-SGC, NFV	5	8	ddC Renal dos. ad	Y		qdh	31	\$42.24
△ ddC, d4T, NFV	8	8	ddC Renal dos. ad, d4T Renal dos. ad	Y	Y	qdh	29	\$42.72
△ ddI, d4T, SQV-SGC	6	9	ddI Renal dos. ad, d4T Renal dos. ad	Y	Y	qdh	13	\$30.86
See More	See All	Top 10	Full Screen Evaluation					

80

Antiretroviral Drugs [Clear All Drugs]

Nucleoside Analogues (NRTI)

⑥ AZT (Retrovir/zidovudine)

⑥ ddI (Videx/didanosine)

⑥ ddC (Hivid/zalcitabine)

⑥ d4T (Videx/didanosine)

⑥ 3TC (Epivir/lamivudine)

⑥ ddT (Aristavirine)

⑥ ABC (Zenagabacavir)

Protease Inhibitors (PI)

⑥ IDV (Chivarin/indinavir)

⑥ SQV-HGC (Invirase/saquinavir)

6/22

77a


77

TO FIG. 6B.











FIG. 6A.

7/22

FROM FIG. 6A.

Therapy Being Evaluated	d4t, d4T, IDV	78 ↖ Use as Current Therapy
 Recommended Dosages <div style="margin-left: 100px;">74</div> <ul style="list-style-type: none"> • Videx 125mg q 12h (4 pills/day, \$4.22/day) • Zerit 15mg q 12h (2 pills/day, \$7.58/day) • Crixivan 800 mg q 8h (6 pills/day, \$15.00/day) <div style="margin-left: 100px;">73</div> <p>(☞) indicates adjusted dosage</p>		
Warning - Resistance Notices		
<ul style="list-style-type: none"> • d4T: Resistance Advisory: Cross Resistance: The patient has at least one previous exposure to AZT that was greater than one year in duration. Previous AZT exposure can lessen the antiRetroviral effect of d4T due to cross resistance. Therapies containing d4T have been ranked lower in their AdjustedScore by +3. • Resistance advisory: IDV: According to the last genotype data entered, the patient's virus currently has the following secondary mutation(s), (L101P), (S4V/P), and (E4V/P) which is/are associated with resistance to IDV. These mutations alone are not enough to preclude the use of IDV but they do indicate a trend in this direction. IDV is still an option but ongoing IDV use may result in a more rapid emergence of complete resistance. The Adjusted Score of IDV has been lowered by +3. <div style="margin-left: 100px;">79</div>		

TPMS








FIG. 6B.

8/22

Icon	Meaning
○	Indicates that there were no critical alerts for the therapy, however, general warnings and advisories should be read in the Therapy Details box.
ⓘ	Indicates that there were no critical alerts for the therapy, however, general warnings and advisories should be read in the Therapy Details box. The book indicates that therapy has been studied and a reference is available to review.
△	Indicates a yellow alert. There is important information about this therapy that must be reviewed.
⚠	Indicates a yellow alert. There is important information about this therapy that must be reviewed. The book indicates that therapy has been studied and a reference is available to review.
!	Indicates a red alert, which means critical and possible life-threatening situation may exist or may be created with this therapy. Information in the Therapy Details section must be read for this therapy to be considered.
! ⓘ	Indicates a red alert, which means critical and possible life-threatening situation may exist or may be created with this therapy. Information in the Therapy Details section must be read for this thereapy to be considered. The book indicates that therapy has been studied and a reference is available to review.
X	Indicates the therapy is not recommended.

FIG. 7.

9/22

TPMS Patient

Medical History | Chart | Therapy Evaluation

Therapy Being Evaluated

AZT, dd, SQV, RTV

78

73b

< Use as Current Therapy

Show Therapies

STOP! - DRUG INTERACTION RED ALERT - STOP!!!

Read the following Red Drug Contra-Indication Alerts for this therapy:

Drug Interaction Alert: Patient is currently taking cisapride, co-administration of Norvir (Ritonavir/RTV) with certain non-sedating antihistamines, sedative hypnotics, or antiarrhythmics may result in potentially serious and/or life-threatening adverse events due to possible effects of Norvir (Ritonavir/RTV) on the hepatic metabolism of certain drugs. Norvir (Ritonavir/RTV) can produce large increases in plasma concentrations of certain highly metabolized drugs. Norvir (Ritonavir/RTV) should not be coadministered with alprazolam, amiodarone, astemizole, bepridil, bupropion, cisapride, clozapine, diazepam, encainide, estazolam, flecainide, flurazepam, mepredine, midazolam, piroxicam, propafenone, propoxyphene, quinidine, rifabutin, terfenadine, triazolam or zolpidem. Patient is taking cisapride and in order to use this therapy, that drug should be replaced with a non-contraindicated substitute. CmiDIL, Commentary25

Dosages

- Retrovir 300mg q 2h (2 pills/day, \$9.56/day)
- Videx 125mg q 2h (4 pills/day, \$4.22/day)
- Inivase 400mg q 2h, taken within 2 hours after a full meal (4 pills/day, \$8.47/day)
- Norvir 400mg q 2h (8 pills/day, \$14.84/day)

(C) indicates adjusted dosage

Dosage Adjustments: The following dosage adjustments messages apply to this therapy.

Dosage Notice: This therapy contains both saquinavir and ritonavir. When ritonavir and saquinavir are used together the dosage of each drug is reduced by 1/3. The dosage for these drugs has been set accordingly. DosDComD, Commentary228

Inivase (saquinavir/SQV): The following Warnings and Advisories apply to Inivase (saquinavir/SQV):

• Drug Interaction Information: Compounds that are substrates of CYP3A4 (e.g., calcium channel blockers, cindamycin, dapsone, quinidine, triazolam) may have elevated plasma concentrations when coadministered with Inivase (saquinavir/SQV); therefore, patient should be monitored for toxicities associated with such drugs when taking Inivase (saquinavir/SQV). CmiGenF, Commentary21

FIG. 8.

SUBSTITUTE SHEET (RULE 26)

10/22

70

76

Therapy Options

Therapy	Eff.	Adj.	Safety
<input type="checkbox"/> d4T, 3TC, IDV	1	1	
<input type="checkbox"/> AZT, 3TC, IDV	1	1	
<input type="checkbox"/> d4T, 3TC, NFV	1	1	
<input type="checkbox"/> AZT, 3TC, NFV	1	1	
<input type="checkbox"/> d4T, 3TC, NFV			
<input type="checkbox"/> AZT, 3TC, NFV			
<input type="checkbox"/> ddI, d4T, 3TC, NFV			
<input type="checkbox"/> d4T, 3TC, NFV			
<input type="checkbox"/> d4T, 3TC, NFV			

90

Show Abstract for Retrovir

Show Abstract for Epivir

Show Abstract for Viracept

Show Therapy Study

Print Details for AZT, 3TC, NFV

Print Top 10 Therapy Option Details

Therapy B Evaluated

General

- Vi
- M

Hide Column "Eff."

Hide Column "Adj."

Hide Column "Safety Considerations"

Show Column "Med"

Show Column "Drug"

Hide Column "Freq."

Hide Column "Pills"

Hide Column "Cost"

FIG. 9.

11/22

50

FIG. 10A.

<div> <div>50a</div> <div>60a</div> <div>70a</div> </div> <div>TPMS Patient</div>		<div>Medical History</div> <div>Chart</div> <div>Therapy Evaluation</div>	
<div>General</div> <div> <div>Patient Id: demo</div> <div>Birth date: 1/1/1960</div> <div>TPMS Number: </div> </div> <div> <div>Physician: </div> <div>Gender: Male</div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>+</div> <div>H</div> </div> <div> <div>□</div> <div>E</div> </div> <div> <div>□</div> <div>E</div> </div> <div> <div>Entry</div> <div>Comment PopUp</div> </div> </div> <div> <div>Weight (kg) +</div> <div>323/1999</div> <div>Date</div> <div>3/3/1999</div> <div>Value</div> <div>55.00</div> </div> <div> <div>Solid Dosage +</div> <div>3/1/1999</div> <div>Yes</div> </div>		<div> <div>Print</div> <div>Save</div> </div>	
<div>CD4 and Viral Load</div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>320</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>340</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>		<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>	
<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>		<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>	
<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>		<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>	
<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>		<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>	
<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>		<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>	
<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>		<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>	
<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>		<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>	
<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>		<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>500</div> </div> </div>	
<div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>12000</div> <div>Specimen Date</div> <div>1/1/1999</div> <div>Prev Value</div> <div>12000</div> </div> </div> <div> <div> <div>+</div> <div>H</div> </div> <div> <div>3/7/1999</div> <div>500</div> <div>Specimen Date</div> <div></div></div></div>			

12/22

70

TPMS Patient

Medical History | Chart | Therapy Evaluation

Evaluate Current Therapy

AZT, 3TC, IDV

Show 1-Drug Therapies

Show 3-Drug Therapies

Show 4-Drug Therapies

Show EAP Therapies

Show Rejected Therapies

Show EAP Therapies

Therapy Options (10 of 98)

Therapy	Eff.	Adj.	Safety Considerations	Freq.	Pills	Cost
Δ ddi, d4T, NVP	2	2	ddi Renal dos Adj, d4T Renal dos Adj	q8h	15	\$30.38
Δ ddi, d4T, RIV	4	4	ddi Renal dos Adj, d4T Renal dos Adj	q12h	18	\$34.06
Δ NVP, ABC, EFV	5	5	NVP Renal dos Adj, EFV+Renal Dyst	q8h	9	\$44.32
Δ DLV, ABC, EFV	5	5	EFV+Renal Dyst	q8h	19	\$43.21
Δ NVP, ABC, EFV	5	5	EFV+Renal Dyst	q8h	16	\$54.40
Δ NVP, NVP, EFV	5	5	NVP Renal dos Adj, EFV+Renal Dyst	q8h	17	\$46.41

See More | See All | Top 10 | Full Screen Evaluation

Therapy Being Evaluated

AZT, 3TC, IDV

<Use as Current Therapy

Antiretroviral Drugs

Clear All Drugs

Nucleoside Analogues (NRTI)

☒ AZT (Retrovir/zidovudine)

☐ ddI (Videx/didanosine)

☐ ddC (Hivid/zalcitabine)

☒ 3TC (Epivir/lamivudine)

☐ d4T (Zeritab/zalcitabine)

☐ ABC (Ziagen/zalcitabine)

Protease Inhibitors (PI)

CAUTION

YELLOW ALERT

CAUTION

• AZT Δ: Medical Condition Alert: This patient has a history of anemia. Use Retrovir with caution due to risk of hematologic toxicity. More Info 171

FitRankC, Commentary171

Recommended Dosages

73

• Retrovir 300mg q12h (2 pills/day, \$9.56/day)

• Epivir 150mg q24h (1 pill/day, \$3.84/day)

• Crixivan 800 mg q8h (6 pills/day, \$15.00/day)

(Δ indicates adjusted dosage)

Warning - Resistance Notices

• Resistance Advisory: Retrovir and Epivir ranked lower (+2) due to historical virological failure. More Info 364 FitResF13, Commentary364

TPMS

Help

Print

Copy


Paste

Find

Close

FIG. 10B.

13/22



14/22

TPMS Patient

Medical History Chart Therapy Evaluation

General

Patient Id: demo1

Physician:

Birth date: 11/11/1980

Gender: Male

TPMS Number:

Weight (kg): 55.00

Solid Dosage: Yes

Comment PopUp

Date: 3/31/1999

Print

Save

CDA and Viral Load

(cells/cubic mm)

Current Viral Load

Previous Viral Load

HIV Genotype

Phenotype

Allergy/Hyper

Intolerance

Hemoglobin

Specimen Date

Neutrophils

Specimen Date

Hepatic Function

Specimen Date

Boundary and Prequalification Messages

Please be aware that the following boundary and prequalification conditions currently apply to this patient

Therapy Initiation/Change Messages

• Poor Viral Suppression Δ : The patient's viral load count either did not decrease $\geq .5$ log from the last point or is not below the viral load reduction goal. Unless lab error is at fault, consider changing therapy. More Info PQ1 PreQualA6, Commentary445

Data Needed Soon - Caution

No Baseline Viral Load Value: Please specify which viral load value or values (an average of two points) you wish to be set as the baseline viral load value for this patient.

BoundSZY, Commentary411a

OK

Cancel

TPMS

TPMS Patient

Medical History Chart Therapy Evaluation

FIG. 10D.

50

FIG. 11A.

16/22

TPMS Patient

Medical History Chart Therapy Evaluation

General

Patient Id:

Physician:

Birth date:

Gender:

TPMS Number:

Print Save

Weight (kg):

Solid Dosage:

Date:

Value:

CD4 and Viral Load

(cells/cubic mm)

Current Viral Load:

Previous Viral Load:

HIV Genotype:

Phenotype:

Allergy/Hyper:

Intolerance:

Hemoglobin:

Specimen Date:

Neutrophils:

Specimen Date:

Hepatic Function:

Specimen Date:

Boundary and Prequalification Messages

Please be aware that the following boundary and prequalification conditions currently apply to this patient

Therapy Initiation/Change Messages

- Therapy Initiation: Current treatment guidelines recommend initiation of antiRetroviral therapy for HIV-infected patients with HIV RNA (viral load) concentrations greater than 20,000 copies/ml (10,000 Eq/ml bDNA) or CD4 counts less than 500 cells/uL (Ann. Int. Med., 1998). PreQualM, Commentary61
- Combination Therapy Recommended: Experts agree that the goal of antiRetroviral therapy should be to reduce the viral load to as low a level as possible for as long as possible. Initiation of therapy with a combination containing 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a potent protease inhibitor have been shown to provide enhanced clinical benefit versus 2 drug combinations with regard to reduction in viral load and improved clinical outcomes. PreQualM, Commentary66

TPMS

Medical History Chart Therapy Evaluation

TPMS

Medical History Chart Therapy Evaluation

FIG. 11B.

17/22

TPMS Patient		Medical History		Therapy Evaluation																																																																							
<input type="checkbox"/> Show 1-Drug Therapies <input checked="" type="checkbox"/> Show 3-Drug Therapies <input type="checkbox"/> Show Rejected Therapies <input type="checkbox"/> Show 2-Drug Therapies <input checked="" type="checkbox"/> Show 4-Drug Therapies <input type="checkbox"/> Show EAP Therapies		<div style="border: 1px solid black; padding: 2px;">None</div>																																																																									
<div style="display: flex; justify-content: space-between;"> <div> Therapy Options (10 of 613) </div> <div> <input type="button" value="Clear All Drugs"/> </div> </div>																																																																											
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Therapy</th> <th>Eff.</th> <th>Adj.</th> <th>Safety Considerations</th> <th>Freq.</th> <th>Pills</th> <th>Cost</th> </tr> </thead> <tbody> <tr> <td><input type="radio"/> AZT, ddI, 3TC, SQV-SGC</td> <td>1</td> <td>1</td> <td></td> <td>q8h</td> <td>26</td> <td>\$43.46</td> </tr> <tr> <td><input type="radio"/> ddI, 3TC, NFV</td> <td>1</td> <td>1</td> <td></td> <td>q8h</td> <td>13</td> <td>\$34.78</td> </tr> <tr> <td><input type="radio"/> AZT, 3TC, IDV</td> <td>1</td> <td>1</td> <td></td> <td>q8h</td> <td>10</td> <td>\$32.24</td> </tr> <tr> <td><input type="radio"/> AZT, 3TC, NFV</td> <td>1</td> <td>1</td> <td></td> <td>q8h</td> <td>13</td> <td>\$35.81</td> </tr> <tr> <td><input type="radio"/> ddI, 3TC, IDV</td> <td>1</td> <td>1</td> <td></td> <td>q8h</td> <td>10</td> <td>\$31.20</td> </tr> <tr> <td><input type="radio"/> AZT, ddI, RTV, DLV</td> <td>2</td> <td>2</td> <td>DLV+RTV</td> <td>q8h</td> <td>30</td> <td>\$45.99</td> </tr> <tr> <td><input type="radio"/> ddI, ddI, RTV, DLV</td> <td>2</td> <td>2</td> <td></td> <td>q8h</td> <td>17</td> <td>\$42.55</td> </tr> <tr> <td><input type="radio"/> ddI, 3TC, RTV</td> <td>2</td> <td>2</td> <td></td> <td>q8h</td> <td>16</td> <td>\$38.46</td> </tr> <tr> <td><input type="radio"/> AZT, ddI, RTV, NVP</td> <td>2</td> <td>2</td> <td></td> <td>q12h</td> <td>20</td> <td>\$47.10</td> </tr> </tbody> </table>						Therapy	Eff.	Adj.	Safety Considerations	Freq.	Pills	Cost	<input type="radio"/> AZT, ddI, 3TC, SQV-SGC	1	1		q8h	26	\$43.46	<input type="radio"/> ddI, 3TC, NFV	1	1		q8h	13	\$34.78	<input type="radio"/> AZT, 3TC, IDV	1	1		q8h	10	\$32.24	<input type="radio"/> AZT, 3TC, NFV	1	1		q8h	13	\$35.81	<input type="radio"/> ddI, 3TC, IDV	1	1		q8h	10	\$31.20	<input type="radio"/> AZT, ddI, RTV, DLV	2	2	DLV+RTV	q8h	30	\$45.99	<input type="radio"/> ddI, ddI, RTV, DLV	2	2		q8h	17	\$42.55	<input type="radio"/> ddI, 3TC, RTV	2	2		q8h	16	\$38.46	<input type="radio"/> AZT, ddI, RTV, NVP	2	2		q12h	20	\$47.10
Therapy	Eff.	Adj.	Safety Considerations	Freq.	Pills	Cost																																																																					
<input type="radio"/> AZT, ddI, 3TC, SQV-SGC	1	1		q8h	26	\$43.46																																																																					
<input type="radio"/> ddI, 3TC, NFV	1	1		q8h	13	\$34.78																																																																					
<input type="radio"/> AZT, 3TC, IDV	1	1		q8h	10	\$32.24																																																																					
<input type="radio"/> AZT, 3TC, NFV	1	1		q8h	13	\$35.81																																																																					
<input type="radio"/> ddI, 3TC, IDV	1	1		q8h	10	\$31.20																																																																					
<input type="radio"/> AZT, ddI, RTV, DLV	2	2	DLV+RTV	q8h	30	\$45.99																																																																					
<input type="radio"/> ddI, ddI, RTV, DLV	2	2		q8h	17	\$42.55																																																																					
<input type="radio"/> ddI, 3TC, RTV	2	2		q8h	16	\$38.46																																																																					
<input type="radio"/> AZT, ddI, RTV, NVP	2	2		q12h	20	\$47.10																																																																					
<div style="display: flex; justify-content: space-between;"> <div> Antiretroviral Drugs </div> <div> <input type="button" value="Clear All Drugs"/> </div> </div>																																																																											
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2">Nucleoside Analogues (NRTI)</th> </tr> </thead> <tbody> <tr><td><input type="checkbox"/> AZT (Retrovir/zidovudine)</td><td></td></tr> <tr><td><input type="checkbox"/> ddI (Videx/didanosine)</td><td></td></tr> <tr><td><input type="checkbox"/> ddC (Hivid/zalcitabine)</td><td></td></tr> <tr><td><input type="checkbox"/> 3TC (Epivir/lamivudine)</td><td></td></tr> <tr><td><input type="checkbox"/> ddT (Zenivir/didanosine)</td><td></td></tr> <tr><td><input type="checkbox"/> ABC (Ziagen/abacavir)</td><td></td></tr> </tbody> <thead> <tr> <th colspan="2">Protease Inhibitors (PI)</th> </tr> </thead> <tbody> <tr><td><input type="checkbox"/> IDV (Cibivir/indinavir)</td><td></td></tr> <tr><td><input type="checkbox"/> SQV-HGC (Invirase/saquinavir)</td><td></td></tr> <tr><td><input type="checkbox"/> SQV-SGC (Fortovase/saquinavir)</td><td></td></tr> </tbody> </table>						Nucleoside Analogues (NRTI)		<input type="checkbox"/> AZT (Retrovir/zidovudine)		<input type="checkbox"/> ddI (Videx/didanosine)		<input type="checkbox"/> ddC (Hivid/zalcitabine)		<input type="checkbox"/> 3TC (Epivir/lamivudine)		<input type="checkbox"/> ddT (Zenivir/didanosine)		<input type="checkbox"/> ABC (Ziagen/abacavir)		Protease Inhibitors (PI)		<input type="checkbox"/> IDV (Cibivir/indinavir)		<input type="checkbox"/> SQV-HGC (Invirase/saquinavir)		<input type="checkbox"/> SQV-SGC (Fortovase/saquinavir)																																																	
Nucleoside Analogues (NRTI)																																																																											
<input type="checkbox"/> AZT (Retrovir/zidovudine)																																																																											
<input type="checkbox"/> ddI (Videx/didanosine)																																																																											
<input type="checkbox"/> ddC (Hivid/zalcitabine)																																																																											
<input type="checkbox"/> 3TC (Epivir/lamivudine)																																																																											
<input type="checkbox"/> ddT (Zenivir/didanosine)																																																																											
<input type="checkbox"/> ABC (Ziagen/abacavir)																																																																											
Protease Inhibitors (PI)																																																																											
<input type="checkbox"/> IDV (Cibivir/indinavir)																																																																											
<input type="checkbox"/> SQV-HGC (Invirase/saquinavir)																																																																											
<input type="checkbox"/> SQV-SGC (Fortovase/saquinavir)																																																																											
<div style="display: flex; justify-content: space-between;"> <div> See More See All Top 10 Full Screen Evaluation </div> <div> <input type="button" value="Use as Current Therapy"/> </div> </div>																																																																											
<div> Therapy Being Evaluated: None </div>																																																																											
<div> General Messages </div>																																																																											
<ul style="list-style-type: none"> • WARNING: Before initiating any antiRetroviral treatment regimen, the complete product information for each therapeutic component should be consulted. W1 • Viral Load Testing Required: Viral load testing should be repeated 21-35 days after initiation of, or a change of, antiRetroviral therapy to evaluate therapeutic efficacy and patient compliance. A1 																																																																											
<div> Therapy Initiation/Change Messages </div>																																																																											
<ul style="list-style-type: none"> • Therapy Initiation: Current treatment guidelines recommend initiation of antiRetroviral therapy for HIV-infected patients with HIV RNA (viral load) concentrations greater than 20,000 copies/ml (10,000 Eq/ml bDNA) or CD4 counts less than 500 cells/μl (Ann. Int. Med., 1998). A2 • Combination Therapy Recommended: Experts agree that the goal of antiRetroviral therapy should be to reduce the viral load to as low a level as possible for as long as possible. Initiation of therapy with a combination containing 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a potent protease inhibitor have been shown to provide enhanced clinical benefit versus 2 drug combinations with regard to reduction in viral load and improved clinical outcomes. A3 																																																																											
<div> TPMS <div style="float: right;"> <input type="button" value="Print"/> <input type="button" value="Save"/> <input type="button" value="Cancel"/> <input type="button" value="Help"/> </div> </div>																																																																											

FIG. 11C.

18/22

60a 70a

FIG. 11D.

TPMS Patient

Medical History Chart Therapy Evaluation

Therapy Being Evaluated

AZT, ddI, RTV, DLV

<Use as Current Therapy

Show Therapies

Recommended Dosages

Retrovir 300mg q 12h (2 pills/day, \$9.56/day)

Videx 200mg q 12h (4 pills/day, \$6.78/day)

Norvir 600 mg q 12h (12 pills/day, \$22.26/day)

Rescriptor 400mg q 8h (12 pills/day, \$7.39/day)

Warnings and Side Effects

- AZT: Interrupt Retrovirus if anemia and/or neutropenia develops. More Info 036 DosGenA, Commentary36
- ddI: When treatment with other drugs known to cause pancreatic toxicity is required (for example, IV pentamidine), suspension of Videx should be considered. CmtGenA, Commentary13
- ddI: If patients develop symptoms of neuropathy, Videx therapy should be interrupted. DosGenB, Commentary40
- ddI: Clinical signs suggestive of pancreatitis should prompt dose suspension of Videx and careful evaluation of the possibility of pancreatitis. Only after pancreatitis has been ruled out should dosing be resumed. DosGenB, Commentary39
- DLV: Skin rash attributable to Rescriptor may occur during first 21 days. More Info 054 CmtGenS, Commentary54

Drug Interaction Information

- ddI: Videx should not be administered with a prescription antibiotic containing any form of tetracycline. CmtGenA, Commentary15
- ddI: Plasma concentrations of some quinolone antibiotics are decreased when administered with antacids containing magnesium or aluminum. Therefore, doses of quinolone antibiotics should not be administered within 2 hours of taking Videx. CmtGenA, Commentary16
- RTV: Monitor for decreased AUC of Norvir and associated adverse events when concomitant with use of drugs that increase CYP3A activity (including tobacco). More Info 026 CmtGenH, Commentary26

19/22

TPMS Patient

Medical History Chart

Therapy Evaluation

Evaluate Current Therapy?

None

☐ Show 1-Drug Therapies
 ☒ Show 2-Drug Therapies
 ☒ Show 3-Drug Therapies
 ☐ Show 4-Drug Therapies
 ☐ Show EAP Therapies
 ☐ Show Rejected Therapies

Therapy Options (10 of 613)	Antiretroviral Drugs	Nucleoside Analogues (NRTI)	Clear All Drugs
<input checked="" type="radio"/> AZT, dd, 3TC, SQV-S <input type="radio"/> dd, 3TC, NFV <input checked="" type="radio"/> AZT, 3TC, IDV <input checked="" type="radio"/> AZT, 3TC, NFV <input type="radio"/> dd, 3TC, IDV <input type="radio"/> AZT, dd, RTV, DLV <input type="radio"/> dd, dd, IDV, NVP <input type="radio"/> dd, 3TC, RTV <input type="radio"/> AZT, dd, RTV, NVP See More	<input type="checkbox"/> AZT (Retrovir/zidovudine) <input type="checkbox"/> dd (Videx/dancsine) <input type="checkbox"/> ddC (Hivid/zalcitabine) <input type="checkbox"/> 3TC (Epivir/lamivudine) <input type="checkbox"/> ddT (Zenilavudine) <input type="checkbox"/> ABC (Ziagen/abacavir) Protease Inhibitors (PI) <input type="checkbox"/> DV (Crixivan/indinavir) <input type="checkbox"/> SQV-HGC (Invirase/saquinavir) <input type="checkbox"/> SQV-SGC (Fortovase/saquinavir)	<div> <div>26</div> <div>\$43.46</div> </div> <div> <div>13</div> <div>\$34.78</div> </div> <div> <div>10</div> <div>\$32.24</div> </div> <div> <div>13</div> <div>\$35.81</div> </div> <div> <div>10</div> <div>\$31.20</div> </div> <div> <div>30</div> <div>\$45.99</div> </div> <div> <div>17</div> <div>\$42.55</div> </div> <div> <div>16</div> <div>\$38.46</div> </div> <div> <div>20</div> <div>\$47.10</div> </div>	

Show Abstract for Retrovir

Show Abstract for Videx

Show Abstract for Epivir

Show Abstract for Fortovase

Show Therapy Study

Print Details for AZT, dd, 3TC, SQV-SGC

Print Top 10 Therapy Option Details

Print All Therapy Option Summaries

Print Top 10 Therapy Option Summaries

Hide Column "Eff."

Hide Column "Adj."

Hide Column "Safety Considerations"

Show Column "Med"

Show Column "Drug"

Hide Column "Freq."

Hide Column "Pills"

Hide Column "Cost"

Therapy Being Evaluated

None

General Message

Therapy Initiation/Change Messages

• WARNING: Before initiating any antiRetroviral treatment regimen, the complete product information for each therapeutic component should be consulted. **ComGenY, Commentary65**

• Viral Load Testing Required: Viral load testing should be repeated 21-35 days after initiation of, or a change of, antiRetroviral therapy to evaluate therapeutic efficacy and patient compliance. **ComGenY, Commentary65**

Therapy Initiation

• Therapy Initiation: Current treatment guidelines recommend initiation of antiRetroviral therapy for HIV-infected patients with HIV RNA (viral load) concentrations greater than 20,000 copies/ml (10,000 Eq/ml bDNA) or CD4 counts less than 500 cells/ul. (Ann. Int. Med., 1998). **PreQualM, Commentary61**

• Combination Therapy Recommended: Experts agree that the goal of antiRetroviral therapy should be to reduce the viral load to as low a level as possible for as long as possible. Initiation of therapy with a combination containing 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a potent protease inhibitor have been shown to provide enhanced clinical benefit versus 2 drug combinations with regard to reduction in viral load and improved clinical outcomes. **PreQualM, Commentary66**

FIG. 11E.

20/22




FIG. 12A.

TPMS Patient		Medical History Chart		Therapy Evaluation																																																		
Evaluate Current Therapy?		<input checked="" type="checkbox"/> 3TC, d4T, NVP																																																				
Show 1-Drug Therapies		<input checked="" type="checkbox"/>		Show Rejected Therapies																																																		
Show 2-Drug Therapies		<input type="checkbox"/>		Show EAP Therapies																																																		
Show 3-Drug Therapies		<input type="checkbox"/>		Show Rejected Therapies																																																		
Show 4-Drug Therapies		<input type="checkbox"/>		Show EAP Therapies																																																		
<div style="float: right; text-align: right;"> </div>																																																						
<div style="text-align: center;"> Antiretroviral Drugs Clean All Drugs </div>																																																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Therapy</th> <th>Eff.</th> <th>Adj.</th> <th>Safety Considerations</th> <th>Freq.</th> <th>Pills</th> <th>Cost</th> </tr> </thead> <tbody> <tr> <td><input checked="" type="radio"/> dd, d4T, NFV</td> <td>2</td> <td>2</td> <td>Ritabutin+NFV</td> <td>qdh</td> <td>15</td> <td>\$33.88</td> </tr> <tr> <td><input type="radio"/> dd, d4T, EFV</td> <td>5</td> <td>5</td> <td></td> <td>qdh</td> <td>9</td> <td>\$28.44</td> </tr> <tr> <td><input type="radio"/> dd, NFV, EFV</td> <td>5</td> <td>5</td> <td>Ritabutin+NFV</td> <td>qdh</td> <td>16</td> <td>\$38.50</td> </tr> <tr> <td><input type="radio"/> d4T, NFV, EFV</td> <td>5</td> <td>5</td> <td>Ritabutin+NFV</td> <td>qdh</td> <td>14</td> <td>\$40.24</td> </tr> <tr> <td><input type="radio"/> ddC, NFV, EFV</td> <td>5</td> <td>7</td> <td>Ritabutin+NFV</td> <td>qdh</td> <td>15</td> <td>\$38.77</td> </tr> <tr> <td><input type="radio"/> ddC, d4T, EFV</td> <td>5</td> <td>7</td> <td></td> <td>qdh</td> <td>8</td> <td>\$28.71</td> </tr> </tbody> </table>						Therapy	Eff.	Adj.	Safety Considerations	Freq.	Pills	Cost	<input checked="" type="radio"/> dd, d4T, NFV	2	2	Ritabutin+NFV	qdh	15	\$33.88	<input type="radio"/> dd, d4T, EFV	5	5		qdh	9	\$28.44	<input type="radio"/> dd, NFV, EFV	5	5	Ritabutin+NFV	qdh	16	\$38.50	<input type="radio"/> d4T, NFV, EFV	5	5	Ritabutin+NFV	qdh	14	\$40.24	<input type="radio"/> ddC, NFV, EFV	5	7	Ritabutin+NFV	qdh	15	\$38.77	<input type="radio"/> ddC, d4T, EFV	5	7		qdh	8	\$28.71
Therapy	Eff.	Adj.	Safety Considerations	Freq.	Pills	Cost																																																
<input checked="" type="radio"/> dd, d4T, NFV	2	2	Ritabutin+NFV	qdh	15	\$33.88																																																
<input type="radio"/> dd, d4T, EFV	5	5		qdh	9	\$28.44																																																
<input type="radio"/> dd, NFV, EFV	5	5	Ritabutin+NFV	qdh	16	\$38.50																																																
<input type="radio"/> d4T, NFV, EFV	5	5	Ritabutin+NFV	qdh	14	\$40.24																																																
<input type="radio"/> ddC, NFV, EFV	5	7	Ritabutin+NFV	qdh	15	\$38.77																																																
<input type="radio"/> ddC, d4T, EFV	5	7		qdh	8	\$28.71																																																
<div style="float: right; text-align: right;"> </div>																																																						
<div style="text-align: center;"> Nucleoside Analogues (NRTI) </div>																																																						
<input checked="" type="radio"/> AZT (Retrovir/zidovudine) <input type="radio"/> ddC (Vidar/didanosine) <input type="radio"/> ddC (Hivid/zalcitabine) <input checked="" type="radio"/> 3TC (Epivir/lamivudine) <input checked="" type="radio"/> d4T (Zenbid/zalcitabine)																																																						
<div style="text-align: center;"> Protease Inhibitors (PI) </div>																																																						
<input type="radio"/> ABC (Zegafaracin)																																																						
<div style="float: right; text-align: right;"> </div>																																																						
<div style="text-align: center;"> Use as Current Therapy </div>																																																						
<div style="float: right; text-align: right;"> </div>																																																						
<div style="text-align: center;"> Therapy Being Evaluated </div>																																																						
<input checked="" type="checkbox"/> 3TC, d4T, NVP																																																						
<div style="float: right; text-align: right;"> </div>																																																						
<div style="text-align: center;"> Therapy Rejected!!! </div>																																																						
This therapy was rejected for the following reason(s) Additional information about the therapy is provided but this therapy is NOT advisable																																																						
<ul style="list-style-type: none"> Viramune (nevirapine/NVP) Resistance Advisory: According to the last genotype data entered, the patient's virus currently has mutation(s) which is/are associated with resistance to Viramune. FIRMUR, Rejection54 Resistance Advisory: According to the last genotype data entered, the patient's virus currently has the following mutations: M184V [RT]. The genotype test displays evidence of the M184V/M184L mutation which is associated with resistance to 3TC. However, this mutant has increased sensitivity to the antiretroviral activity of AZT and ADV so an AZT/3TC or AZT/ADV combination is still useable. Therefore combinations which contain AZT/3TC and AZT/ADV are shown as therapy options although these therapies have been ranked down +5 in favor of three drug combinations with no resistant mutants. FIRMUR, Rejection51 Epivir and Viramune Resistance Advisory: The patient's last phenotypic assay demonstrates phenotypic resistance to Epivir and Viramune, therefore, therapies containing Epivir and Viramune are not recommended at this time. FIRMUR, Rejection42 NVP Drug Interaction Alert: Patient is currently taking ritabutin and there is insufficient data to assess whether dose adjustments are necessary. These drugs 																																																						
<div style="float: right; text-align: right;"> </div>																																																						
<div style="text-align: center;"> CAUTION YELLOW ALERT CAUTION </div>																																																						
<div style="float: right; text-align: right;"> </div>																																																						
<div style="text-align: center;"> W3 </div>																																																						

22/22

FIG. 12C.

TPMS Patient		Medical History		Chart		Therapy Evaluation	
<div> <div>General</div> <div> <div> <div>Birth date:</div> <div>1/1/1980</div> </div> <div> <div>TPMS Number:</div> <div></div> </div> </div> <div> <div>Physician:</div> <div>patient</div> </div> <div> <div>Gender:</div> <div>Male</div> </div> <div> <div>Print</div> <div>Save</div> </div> </div>		<div> <div>Weight (kg)</div> <div>160.00</div> </div> <div> <div>Solid Dosage</div> <div>Yes</div> </div>		<div> <div>Date</div> <div>1/28/1999</div> </div> <div> <div>Date</div> <div>1/28/1999</div> </div>		<div> <div>Value</div> <div>160.00</div> </div> <div> <div>Value</div> <div>Yes</div> </div>	
<div> <div>CD4 and Viral Load</div> <div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>240</div> </div> </div> <div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Prev Value</div> <div>265</div> </div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>21500</div> </div> </div> <div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>2600</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>265</div> </div> </div> <div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>21500</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>2600</div> </div> </div> <div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>265</div> </div> </div>	
<div> <div>HIV Genotype</div> <div> <div> <div>Specimen Date</div> <div>3/15/1999</div> </div> <div> <div>Value</div> <div>[L10]P, M46[P], 154V[P], V82A[P], M41L[R], Y181</div> </div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>3/15/1999</div> </div> <div> <div>Value</div> <div>[L10]P, M46[P], 154V[P], V82A[P], M41L[R], Y181</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>3/15/1999</div> </div> <div> <div>Value</div> <div>[L10]P, M46[P], 154V[P], V82A[P], M41L[R], Y181</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>3/15/1999</div> </div> <div> <div>Value</div> <div>[L10]P, M46[P], 154V[P], V82A[P], M41L[R], Y181</div> </div> </div>	
<div> <div>Ph</div> <div>AI</div> <div>In</div> </div>		<div> <div> <div>Specimen Date</div> <div>3/15/1999</div> </div> <div> <div>Value</div> <div>[L10]P, M46[P], 154V[P], V82A[P], M41L[R], Y181</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>3/15/1999</div> </div> <div> <div>Value</div> <div>[L10]P, M46[P], 154V[P], V82A[P], M41L[R], Y181</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>3/15/1999</div> </div> <div> <div>Value</div> <div>[L10]P, M46[P], 154V[P], V82A[P], M41L[R], Y181</div> </div> </div>	
<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>15.00</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>No</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>No</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>No</div> </div> </div>	
<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>1500</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>No</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>No</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>No</div> </div> </div>	
<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>25</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>25</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>25</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>25</div> </div> </div>	
<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>1.00</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>1.00</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>1.00</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>1.00</div> </div> </div>	
<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>84.17</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>84.17</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>84.17</div> </div> </div>		<div> <div> <div>Specimen Date</div> <div>1/28/1999</div> </div> <div> <div>Value</div> <div>84.17</div> </div> </div>	




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G06F 17/60, 17/30		A3	(11) International Publication Number: WO 99/52025
			(43) International Publication Date: 14 October 1999 (14.10.99)
(21) International Application Number: PCT/US99/07171		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 1 April 1999 (01.04.99)			
(30) Priority Data: 60/080,629 3 April 1998 (03.04.98) US			
(71) Applicant (for all designated States except US): TRIANGLE PHARMACEUTICALS, INC. [US/US]; 4 University Place, 4611 University Drive, Durham, NC 27707 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): BARRY, David, W. [US/US]; 1810 South Lakeshore Drive, Chapel Hill, NC 27514 (US). UNDERWOOD, Carolyn, S. [US/US]; 108 Parchment Court, Cary, NC 27511 (US). MCCREEDY, Bruce, J. [US/US]; 100 Berryhill Drive, Raleigh, NC 27615 (US). HADDEN, David, D. [US/US]; 2307 Whitley Drive, Durham, NC 27707 (US). LUCAS, Jason, L. [US/US]; 1215 Gateway Lane, West Chester, PA 19355 (US).			
(74) Agents: BODDIE, Needham, J., II et al.; Myers, Bigel, Sibley, & Sajovec, P.A., P.O. Box 37428, Raleigh, NC 27627 (US).			
		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
		(88) Date of publication of the international search report: 2 December 1999 (02.12.99)	

(54) Title: SYSTEMS, METHODS AND COMPUTER PROGRAM PRODUCTS FOR GUIDING THE SELECTION OF THERAPEUTIC TREATMENT REGIMENS

(57) Abstract

Systems, methods and computer program products for guiding selection of a therapeutic treatment regimen for a known disease such as HIV infection are disclosed. The method comprises (a) providing patient information to a computing device (11) (the computer device comprising: a first knowledge base comprising a plurality of different therapeutic treatment regimens for the disease (11); a second knowledge base comprising a plurality of expert rules for selecting a therapeutic treatment regimen for the disease (11); and a third knowledge base comprising advisory information useful for the treatment of a patient with different constituents of the different therapeutic treatment regimens (11); and (b) generating in the computing device a listing (preferably a ranked listing) of therapeutic treatment regimens for the patient (12); and (c) generating in the computing device advisory information (13) for one or more treatment regimens in the listing based on the patient information and the expert rules.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/07171

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : G06F 17/60, 17/30

US CL : 705/3,2,1; 706/45, 10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 705/3,2,1; 706/45, 10

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,517,405 A (MCANDREW et al) 14 MAY 1996, Col. 2, lines 37-41, Col. 3, lines 6-17 and 49-53, Col. 6, line 29-Col. 7 line 54, Col. 8, lines 38-48 and Figures 1 and 2	1-3, 5-10, 13-26, 28-33, 36-49, 51-55, 58-69
Y	Pazzani et al, Application of an Expert System in the Management of HIV-Infected Patients, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 15, No. 5, pages 356-362, 1997	1-3, 5-10, 13-26, 28-33, 36-49, 51-55, 58-69
Y	US 4,839,822 A (DORMOND et al) 13 JUNE 1989, Column 1-Column 3	1, 6, 24, 47
Y	US 5,299,121 A (BRILL et al) 29 MARCH 1994, Column 1-Column 3	1, 24, 47

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 SEPTEMBER 1999

Date of mailing of the international search report

22 OCT 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

TODD JOELTZ

Telephone No. (703) 305-3900

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/07171

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	Evans et al, A Computer-Assisted Management Program for Antibiotics and Other Antiinfective Agents, The New England Journal of Medicine, Vol. 338, No. 4, pages 232-238, 22 January 1998	1-3, 5-10, 13-26, 28-33, 36-49, 51-55, 58-69